The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 23, 2022

Filed:

Sep. 12, 2018
Applicants:

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Katherine E. Lewis, Lake Forest Park, WA (US);

Serena Kimi Perna, Philadelphia, PA (US);

Michael Carleton, Princeton, NJ (US);

Ke Xu, Plainsboro, NJ (US);

Penny Phillips, Morristown, NJ (US);

Dimple Pandya, Princeton, NJ (US);

Brian Wong, Los Altos, CA (US);

Julie Hambleton, San Francisco, CA (US);

Robert Sikorski, Woodside, CA (US);

Emma Masteller, Redwood City, CA (US);

Kevin Hestir, Kensington, CA (US);

David Bellovin, San Jose, CA (US);

Janine Powers, Alameda, CA (US);

Ernestine Lee, Kensington, CA (US);

Assignees:

Five Prime Therapeutics, Inc., Thousand Oaks, CA (US);

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/69 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/513 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 31/337 (2013.01); A61K 31/513 (2013.01); A61K 31/7068 (2013.01); A61K 39/3955 (2013.01); A61K 47/643 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).


Find Patent Forward Citations

Loading…